HomeNewsPodcastCoronavirus Essential podcast | Serum Institute clarifies vaccine availability; Blood Pressure drugs may help in COVID-19 survival, says study

Coronavirus Essential podcast | Serum Institute clarifies vaccine availability; Blood Pressure drugs may help in COVID-19 survival, says study

Tune in to the Coronavirus Essential podcast with Sakshi Batra to know more.

Moneycontrol News
August 24, 2020 / 19:15 IST
Story continues below Advertisement
Remove Ad

Serum Institue of India (SII) issued a statement on August 23, clarifying that all claims surrounding the availability of its COVID-19 vaccine, COVISHIELD, in 73 days are false. The phase 3 trials for the vaccine is still underway in 17 different sites in India.

Story continues below Advertisement
Remove Ad

In another development, a new study has shown that drugs for the high blood pressure may improve COVID-19 survival rates. The study, conducted by the University of East Anglia in the UK, also found that the risk of severe illness and death was reduced by hypertension medications.

Tune in to the Coronavirus Essential podcast with Sakshi Batra to know more.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
 View more
+ Show
Moneycontrol News
first published: Aug 24, 2020 07:15 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Follow Us On:
News
Business New Market New Stocks Income Tax Calculator Election Schedule 2024 India News Economy Mutual Funds Personal Finance IPO News Startups New USA Elections New
Features
Gold Rate Today Silver Rate Today Trending News Startups New National News MC Videos MC You Tube
Tools
SIP Calculator 2 SIP Calculator 3 SIP Calculator 1 New SIP Calculator 4
Specials
PowerYourTrade Master Your Money Game Changers
Network 18 Sites
News18 Firstpost CNN News18 CNBC TV18 Forbes History TV18
Personal Finance
Home Loans up to 50 Lakhs Credit Cards Lifetime Free Finance Tracker Fixed Deposits Fixed Deposit Comparison Fixed Income Account Aggregator
Quick Links
About Us New Contact Us Advisory Alert New Advertise with Us New Disclaimer Privacy Policy Cookie Policy Terms & Conditions Careers Financial Terms (Glossary) Analytical & Information Tool New
Download MC Apps:

Copyright © Network18 Media & Investments Limited. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.